Conserved Therapy
Phase 2Cell therapy
Conserved Therapy is one of 45 small molecule programs targeting Liver Failure. It is currently in Phase 2.
2
Indications
5
Total Trials
0
Active Trials
44
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
252 competitors in Cirrhosis
#DrugCompanyPhaseTrials
1Proamatine
TakedaPreclinical
Crestor
AstraZenecaPreclinical
Thalomid
Bristol-Myers SquibbPreclinical
Farxiga
AstraZenecaPreclinical
Azulfidine
PfizerPreclinical
Dobutrex
Eli LillyPreclinical
HEPCLUDEX
GileadPreclinical
Coreg
Akero TherapeuticsPreclinical
Baraclude
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
Conserved Therapy
SSun Yat-sen University
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Cirrhosis4 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Conserved Therapy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 2[1]
- Company
- SSun Yat-sen University